Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03039621
Recruitment Status : Completed
First Posted : February 1, 2017
Results First Posted : April 27, 2020
Last Update Posted : May 5, 2020
Sponsor:
Information provided by (Responsible Party):
Materia Medica Holding

Tracking Information
First Submitted Date  ICMJE December 28, 2016
First Posted Date  ICMJE February 1, 2017
Results First Submitted Date  ICMJE March 18, 2020
Results First Posted Date  ICMJE April 27, 2020
Last Update Posted Date May 5, 2020
Actual Study Start Date  ICMJE October 7, 2016
Actual Primary Completion Date January 9, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 27, 2020)
Time to Alleviation of All ARVI Symptoms. [ Time Frame: 14 days of observation. ]
Based on patient diary data. Criteria of alleviation of all ARVI symptoms: oral temperature ≤37.5С for 24 hours (without subsequent increase within the observation period) + absence of ARVI symptoms /presence of ARVI symptoms with ≤3-point of the total score (TS) according to the 4-point scale (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom, for each flu-like nonspecific and respiratory symptom). TS ranges from 0 to 30, and the higher scores mean a worse outcome.
Original Primary Outcome Measures  ICMJE
 (submitted: January 30, 2017)
Time to the alleviation of all symptoms of the acute respiratory viral infection based on patient diary data [ Time Frame: From the time of randomization until the time of alleviation of all symptoms, assessed up to 10 days ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 27, 2020)
  • Time to Normalization of Body Temperature. [ Time Frame: 14 days of observation. ]
    Based on patient diary data. Oral temperature ≤37.5С for 24 hours (without subsequent increase within the observation period).
  • Time to Alleviation of Flu-like Nonspecific Symptoms. [ Time Frame: 14 days of observation. ]
    Based on patient diary data. Absence of flu-like nonspecific symptoms/presence of one mild flu-like nonspecific symptom.
  • Time to Alleviation of Respiratory Symptoms. [ Time Frame: 14 days of observation. ]
    Based on patient diary data. Absence of respiratory symptoms/presence of one mild respiratory symptom.
  • Flu-like Nonspecific and Respiratory Symptoms Total Score (TS) for Days 2-6. [ Time Frame: On days 2-6 of the observation period. ]
    Based on patient diary data. The total score (TS) ranges from 0 to 30 consisting of 4 flu-like nonspecific (decreased activity/weakness, poor appetite/refusal to eat, sick appearance, sleep disturbance) and 6 respiratory (runny nose, stuffy nose/nasal congestion, sneezing, hoarseness, sore throat, cough) symptoms according to the 4-point scale for each symptom (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). TS ranges from 0 to 30, and the higher scores mean a worse outcome.
  • ARVI Severity. [ Time Frame: On days 2-6 of the observation period. ]
    Based on the area under the curve of TS for days 2-6, according to the patient diary. The total score (TS) will be calculated based on the severity of each ARVI symptom (sum of 11 symptoms = body temperature, flu-like nonspecific symptoms (4 symptoms) and respiratory symptoms (6 symptoms) according to the 4-point scale (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TS the absolute oral temperature values, measured in degrees Celsius, will be converted into relative units (or points), given the following gradations: ≤37.5С = 0 point; 37.6-38.1C = 1 point; 38.2-38.8C = 2 points; ≥38.90С = 3 points. For total score minimum and maximum scores are 0 and 33, where higher values represent a worse outcome.
  • Percentage of Recovered Patients. [ Time Frame: On days 2-6 of the observation period. ]
    Based on patient diary data. Criteria of recovery/alleviation of all ARVI symptoms: oral temperature ≤37.5С for 24 hours (without subsequent increase within the observation period) + absence of ARVI symptoms /presence of ARVI symptoms with ≤3-point of the total score (TS) according to the 4-point scale for each flu-like nonspecific and respiratory symptom (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom, for each flu-like nonspecific and respiratory symptom).
  • Rates of Antipyretics Use Per Patient. [ Time Frame: On days 1- 5 of the treatment period. ]
    Based on patient diary data. The number of intakes of prescribed antipyretics.
  • Percentage of Patients With Worsening of Illness. [ Time Frame: 14 days of observation peiod. ]
    Based on patient diary data. The disease worsening: ARVI complications, including those requiring antibiotics; hospitalization).
Original Secondary Outcome Measures  ICMJE
 (submitted: January 30, 2017)
  • Time to a normal body temperature [ Time Frame: From the time of randomization until the time of normal body temperature, assessed up to 10 days ]
  • Time to the alleviation of general/non-specific symptoms [ Time Frame: From the time of randomization until the time of absence of general/non-specific symptoms, assessed up to 10 days ]
  • Time to the alleviation of nasal/throat/chest symptoms [ Time Frame: From the time of randomization until the time of absence of nasal/throat/chest symptoms, assessed up to 10 days ]
  • Total severity scores of disease based on patient diary data [ Time Frame: Study entry, Days 2-6 ]
    based on patient diary data
  • Severity of acute respiratory viral infection based on patient diary data [ Time Frame: Study entry, Days 1-6 ]
    area under the curve for the total severity scores
  • Percentage of patients with recovery based on patient diary data [ Time Frame: Study entry, Days 1-6 ]
  • Number of antipyretic use (for prescribed indications) based on patient diary data [ Time Frame: Study entry, Days 1-6 ]
  • Percentage of patients with complications of acute respiratory viral infection, including those requiring antibiotic administration or hospitalization) [ Time Frame: From the time of randomization up to 14 days ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children
Official Title  ICMJE International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children
Brief Summary The international multicenter double-blind placebo-controlled randomized clinical study in parallel groups.The objective of this study is to obtain additional data on the efficacy and safety of Ergoferon in the treatment of acute respiratory viral infections (ARVI) in children aged from 6 months to 6 years old.
Detailed Description

Study design: international, multicenter double-blind placebo-controlled randomized clinical study in parallel groups.

The study will enroll patients of either gender aged from 6 months to 6 years old with clinical manifestations of ARVI within the first days after the onset of the disease. Patients will be included evenly (1:1 ratio) in accordance with the age group: 6 months - 3 years 11 months 29 days; 4 years - 6 years 11 months 29 days. Signed information sheet for parents/adopters (inform consent form) will be obtained from all participant's parents/ adopters prior to the screening procedures. Medical history, thermometry, patient examination by the doctor, assesment of ARVI symptoms severity and nasopharyngeal swabswill be performed at screening visit (Day 1).

If the inclusion criteria are met and exclusion criteria are absent, the patient is included in the study.

Nasopharyngeal swabs will be analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR) to identify the most common respiratory viruses, including (1) Influenza A virus; (2) Influenza B virus; (3) Influenza A (H1N1)pdm; (4) Human metapneumovirus; (5) Human respiratory syncytial virus; (6) Human rhinovirus; (7) Human adenovirus; (8) Human bocavirus; (9) Human parainfluenza virus 1; (10) Human parainfluenza virus 2; (11) Human parainfluenza virus 3; (12) Human parainfluenza virus 4; (13) Human coronavirus OC43; (14) Human coronavirus 229E; (15) Human coronavirus HKU1; (16) Human coronavirus NL63.

The patients are randomized into one of two groups: the 1st group patients will take Ergoferon according to the dosage regimen for 5 days; the 2nd group patients will take Placebo according to the dosage regimen of Ergoferon for 5 days. Patient's parents/ adoptive parents are provided with diares, where daily in the morning and at hight they record oral temperature (measured by a digital thermometer provided by Sponsor), symptoms of ARVI (according to the 4-points scale), administered drug and concomitant therapy. The doctors instruct parents/ adoptive parents how to fill in the diaries; the first scores of ARVI symptoms severity and oral temperature are made by doctors together with the parents/adoptive parents.

Patients are observed up for 14 days (screening and randomization - up to 1 day, therapy for 5 days, follow-up from 6 to 10 days; delayed telephone "visit" - on day 14).

During the observation period, two visits are planned (at home or at the medical center) on day 3 (Visit 2) and day 6 (Visit 3). If patients still have any symptoms of ARVI/ complications of ARVI, then an additional (unscheduled) Visit 4 is provided on Day 10 of the observation (at the medical center). During Visits 2, 3 (4), doctors carry out an physical examination, record dynamics of ARVI symptoms and concomitant therapy, check patient's diaries, which parents/adoptive parents return back at Visit 3 or 4. At Visit 3 (after 5 days of therapy) compliance with the treatment is additionally assessed. A "telephone visit" (Visit 5, Day 14 ± 1) is carried out to interview parents about the patient's condition, presence/ absence of complications, and possible use of antibiotics.

During the study, symptomatic therapy and therapy for underlying chronic conditions are allowed with the exception of the drugs indicated in the section "Prohibited Concomitant Therapy".

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Acute Respiratory Viral Infections
Intervention  ICMJE
  • Drug: Ergoferon
    For oral use.
  • Drug: Placebo
    For oral use.
Study Arms  ICMJE
  • Experimental: Ergoferon
    Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
    Intervention: Drug: Ergoferon
  • Placebo Comparator: Placebo
    Placebo using Ergoferon scheme.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 10, 2019)
287
Original Estimated Enrollment  ICMJE
 (submitted: January 30, 2017)
288
Actual Study Completion Date  ICMJE January 9, 2019
Actual Primary Completion Date January 9, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients of both genders aged from 6 months to 6 years old.
  2. ARVI based on medical examination: oral temperature of at least 38.0°C at examination + total symptom severity ≥5.
  3. The first 24 hours after ARVI onset.
  4. Seasonal raise in ARVI incidence.
  5. Availability of signed information sheet for parents/adopters(Informed Consent Form) for participation in the clinical trial.

Exclusion Criteria:

  1. Suspected pneumonia or bacterial infection (e.g. meningitis, sepsis, otitis media, urinary tract infection, etc.) requiring a prescription of antibacterial product from the first day of the disease.
  2. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic diseases of connective tissue, oncohaematological and other diseases).
  3. Clinical symptoms of severe influenza infection/ARVI requiring hospitalization.
  4. Medical history of primary and secondary immunodeficiency; oncologic conditions.
  5. Aggravation or decompensation of chronic disease (diabetes mellitus, cerebral palsy, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of the respiratory and ETN organs/ear, throat, mouth, tongue, larynx, trachea, neck and salivary and thyroid glands, etc.) which affect the patient's ability to participate in the clinical study.
  6. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
  7. Allergy/hypersensitivity to any components of the drug product used in the therapy.
  8. Course administration of the drug products specified in the section "Prohibited Concomitant Therapy" within two weeks prior to inclusion in the study.
  9. Patients whose parents/adoptive parents will not fulfil the requirements during the study or follow the order of administration of the studied drug products from the investigator's point of view.
  10. Participation in other clinical trials within 3 months prior to the enrollment in this study.
  11. The patient's parent/adoptive parent is a study specialist at the centre and is directly involved in the study or is an immediate family member of the investigator. Spouses parents, children or siblings, regardless of whether they are siblings or adopted are considered immediate family members.
  12. The patient's parent/adoptive parent works at OOO "NPF "MATERIA MEDICA HOLDING", i.e. they are employees of the Company, temporary employees on a contract basis or appointed official responsible for conduction of the study or their immediate family members.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Months to 6 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Kazakhstan,   Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03039621
Other Study ID Numbers  ICMJE MMH-ER-009
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Materia Medica Holding
Study Sponsor  ICMJE Materia Medica Holding
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Materia Medica Holding
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP